# US 2017/0319515 A1 · Ophthalmic compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0319515 A1
- Document ID: US20170319515A1
- Status: Published application
- Kind: A1
- Application number: 15/587,764
- Filed: 2017-05-05
- Published: 2017-11-09
- Earliest claimed: 2016-05-06
- Assignees: SaCSh Corp.
- Applicants: SaCSh Corp.
- Inventors: Uri Shabto
- Web page: https://patentgrep.com/patent/US20170319515A1

## CPC

- A61K 31/155: Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/186: {Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide}
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/38: Cellulose; Derivatives thereof
- A61P 27/02: Ophthalmic agents
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 33/04: Amoebicides
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Provided herein is an ophthalmic composition including a therapeutic active agent and an anti-inflammatory agent, in which the active agent is at least about 0.01% w/v of chlorhexidine, derivatives, or analogues of chlorhexidine, or a pharmaceutically acceptable salt, solvent, hydrate, or polymorph thereof. Methods for treating or preventing ocular disease or infection in a subject in need thereof are also provided. The method may include administering to an eye of a subject an ophthalmic composition including chlorhexidine, derivatives, or analogues of chlorhexidine, or a pharmaceutically acceptable salt, solvent, hydrate, or polymorph thereof, and an anti-inflammatory agent. The chlorhexidine, derivatives, or analogues of chlorhexidine, or a pharmaceutically acceptable salt, solvent, hydrate, or polymorph thereof and the anti-inflammatory agent are present in an amount effective to treat or prevent the ocular disease or infection in a subject in need thereof.

## Claims

### Claim 1

An ophthalmic composition comprising:
a therapeutic active agent and an anti-inflammatory agent, wherein the active agent is at least about 0.01% w/v of chlorhexidine, derivatives, or analogues of chlorhexidine, or a pharmaceutically acceptable salt, solvent, hydrate, or polymorph thereof.

### Claim 2 (depends on 1)

The ophthalmic composition of claim 1, wherein the active agent is at a concentration of about 0.01% w/v to about 1.0% w/v.

### Claim 3 (depends on 1)

The ophthalmic composition of claim 1, wherein the active agent is at a concentration of about 0.01% w/v to about 0.5% w/v.

### Claim 4 (depends on 1)

The ophthalmic composition of claim 1, wherein the anti-inflammatory agent comprises a steroidal anti-inflammatory or a non-steroidal anti-inflammatory agent or both.

### Claim 5 (depends on 1)

The ophthalmic composition of claim 1, wherein the anti-inflammatory agent comprises dexamethasone, diflurprednate, loteprednol, prednisolone acetate, ketotifen fumarate, diclofenac sodium, flurbiprofen sodium, ketorolac tromethamine, suprofen, celecoxib, naproxen, or rofecoxib, or a combination thereof.

### Claim 6 (depends on 1)

The ophthalmic composition of claim 1, wherein the anti-inflammatory agent is at a concentration of about 0.025% w/v to about 2.0% w/v.

### Claim 7 (depends on 1)

The ophthalmic composition of claim 1, further comprising a preservative.

### Claim 8 (depends on 7)

The ophthalmic composition of claim 7, wherein the preservative comprises benzalkonium chloride, thimerosal, chlorobutanol, methyl paraben, propyl paraben, phenylethyl alcohol, edetate disodium sorbic acid, or Onamer M, or a combination thereof or a combination thereof.

### Claim 9 (depends on 1)

The ophthalmic composition of claim 1, further comprising a co-solvent.

### Claim 10 (depends on 9)

The ophthalmic composition of claim 9, wherein the co-solvent comprises polysorbate 20, polysorbate 60, polysorbate 80, Pluronic F-68, Pluronic F-84 Pluronic P-103, or cyclodextrin, or a combination thereof.

### Claim 11 (depends on 10)

The ophthalmic composition of claim 10, wherein the co-solvent is present in an amount of about 0.01% w/v to about 2.0% w/v.

### Claim 12 (depends on 1)

The ophthalmic composition of claim 1, further comprising a viscosity agent.

### Claim 13 (depends on 12)

The ophthalmic composition of claim 12, wherein the viscosity agent comprises polyvinyl alcohol, polyvinyl pyrrolidone, methyl cellulose, hydroxy propyl methylcellulose, hydroxyethyl cellulose, carboxymethyl cellulose, or hydroxy propyl cellulose, or a combination thereof.

### Claim 14 (depends on 13)

The ophthalmic composition of claim 13, wherein the viscosity agent is present in an amount of about 0.01% w/v to about 2.0% w/v.

### Claim 15

A method for treating or preventing ocular disease or infection in a subject in need thereof comprising:
administering to an eye of a subject in need thereof an ophthalmic composition comprising a therapeutic active agent and an anti-inflammatory agent, wherein the active agent is at least about 0.01% w/v of chlorhexidine, derivatives, or analogues of chlorhexidine, or a pharmaceutically active salt, solvent, hydrate, or polymorph thereof; and
wherein the active agent and the anti-inflammatory agent are present in an amount effective to treat or prevent the ocular disease or infection in the eye of the subject.

### Claim 16 (depends on 15)

The method of claim 15, wherein the ophthalmic composition is formulated as a solution, suspension, semi-liquid, emulsion, ointment, cream, foam gel, powder or a controlled-release/sustain-release formulation.

### Claim 17 (depends on 15)

The method of claim 15, wherein the ocular disease comprises conjunctivitis, blepharitis, or keratitis.

### Claim 18 (depends on 15)

The method of claim 15, wherein the amount of ophthalmic composition is effective to treat or prevent infection following an ophthalmic surgery or an ophthalmic procedure.

### Claim 19 (depends on 15)

The method of claim 15, wherein the ophthalmic composition is administered topically.

### Claim 20 (depends on 15)

The method of claim 15, wherein the ophthalmic composition is administered to the eye in a concentration of about 0.001 mg to about 5.0 mg of the active agent per eye.

### Claim 21 (depends on 15)

The method of claim 15, wherein the ophthalmic composition is administered to the eye in an amount of about 50 μL to about 80 μL per eye.

### Claim 22 (depends on 15)

The method of claim 15, wherein the ocular disease or infection is of bacterial, mycobacterial, fungal, viral, or amoebal origin.

### Claim 23 (depends on 1)

The ophthalmic composition of claim 1, wherein the ophthalmic composition is formulated as a solution, suspension, semi-liquid, emulsion, ointment, cream, foam gel, powder or a controlled-release/sustain-release formulation.

### Claim 24 (depends on 15)

The method of claim 15, wherein the active agent is at a concentration of about 0.01% w/v to about 1.0% w/v.

### Claim 25 (depends on 15)

The method of claim 15, wherein the active agent is at a concentration of about 0.01% w/v to about 0.5% w/v.

### Claim 26 (depends on 15)

The method of claim 15, wherein the anti-inflammatory agent comprises a steroidal anti-inflammatory or a non-steroidal anti-inflammatory agent or both.

### Claim 27 (depends on 15)

The method of claim 15, wherein the anti-inflammatory agent comprises dexamethasone, diflurprednate, loteprednol, prednisolone acetate, ketotifen fumarate, diclofenac sodium, flurbiprofen sodium, ketorolac tromethamine, suprofen, celecoxib, naproxen, or rofecoxib, or a combination thereof.

### Claim 28 (depends on 15)

The method of claim 15, wherein the anti-inflammatory agent is at a concentration of about 0.025% w/v to about 2.0% w/v.

### Claim 29 (depends on 15)

The method of claim 15, the ophthalmic composition further comprising a preservative.

### Claim 30 (depends on 29)

The method of claim 29, wherein the preservative comprises benzalkonium chloride, thimerosal, chlorobutanol, methyl paraben, propyl paraben, phenylethyl alcohol, edetate disodium sorbic acid, or Onamer M, or a combination thereof or a combination thereof.

### Claim 31 (depends on 15)

The method of claim 15, further comprising a co-solvent.

### Claim 32 (depends on 15)

The method of claim 15, wherein the co-solvent comprises polysorbate 20, polysorbate 60, polysorbate 80, Pluronic F-68, Pluronic F-84 Pluronic P-103, or cyclodextrin, or a combination thereof.

### Claim 33 (depends on 32)

The method of claim 32, wherein the co-solvent is present in an amount of about 0.01% w/v to about 2.0% w/v.

### Claim 34 (depends on 15)

The method of claim 15, the ophthalmic composition further comprising a viscosity agent.

### Claim 35 (depends on 34)

The method of claim 34, wherein the viscosity agent comprises polyvinyl alcohol, polyvinyl pyrrolidone, methyl cellulose, hydroxy propyl methylcellulose, hydroxyethyl cellulose, carboxymethyl cellulose, or hydroxy propyl cellulose, or a combination thereof.

### Claim 36 (depends on 34)

The method of claim 34, wherein the viscosity agent is present in an amount of about 0.01% w/v to about 2.0% w/v.
